Skip to main content
. Author manuscript; available in PMC: 2015 Apr 15.
Published in final edited form as: J Neuroimmunol. 2014 Feb 4;269(0):20–27. doi: 10.1016/j.jneuroim.2014.01.013

Figure 2. Metyrapone treatment reduces body weight and improves glycemic control.

Figure 2

(A), db/db mice treated with metyrapone (db/Met) gained significantly less weight over the fourteen days of treatment, relative to db/db mice treated with vehicle (db/Veh) mice. (B), The weight of the epididymal fat depot is significantly reduced in db/Met mice. (C), Comparable increases in food intake in db/db mice receiving vehicle or metyrapone. (D), Glycemic profiles following glucose challenge are improved following metyrapone treatment in db/db mice. (E), Insulin responses to glucose challenge are also improved following metyrapone treatment in db/db mice. (F), Insulin sensitivity, as measured through insulin tolerance testing, is improved with metyrapone administration in db/db mice. For all graphs, asterisk (*) indicates statistical significance at p<0.05 following 2×2 ANOVA (B-C), or 2×2 repeated measures ANOVA (A, D-F) and error bars depict the s.e.m.